Introduction
Chronic heart disease is the leading cause of death in both men and women in the United States, and coronary artery disease (CAD) constitutes the number one cause among them. The estimated annual incidence of new and recurrent myocardial infarction (MI) in the United States is 865 000 events [1 ] with ST-segment elevation myocardial infarction (STEMI) comprising an estimated 500 000 events per year [2] . Acute STEMI usually occurs when a thrombus forms on a ruptured atheromatous plaque and occludes an epicardial coronary artery. Patient survival depends on several factors, the most important being restoration of brisk antegrade coronary flow, the time taken to achieve this, and the sustained patency of the infarct-related coronary artery. Thrombolysis and percutaneous coronary intervention (PCI) constitute the two approaches for achieving acute reperfusion of the occluded artery and thus reducing infarct size, minimizing myocardial damage, preserving left ventricular function, and decreasing morbidity and mortality [3] .
Current clinical practice guidelines of the American College of Cardiology (ACC)/American Heart Association (AHA) have established the standard of care benchmark for door-to-balloon time of 90 min or less among patients presenting with STEMI [4 ] , yet only about 20-25% of all US hospitals are capable of providing 24/7 PCI. Thus, it is imperative to form a framework of reperfusion strategies that will minimize the total ischemia time in these patients (i.e., from symptom onset to the time of either mechanical or pharmacologic reperfusion). According to data a published from the Global Registry of Acute Coronary Events (GRACE), approximately one-third of patients with STEMI who are eligible for reperfusion therapy do not receive either primary PCI or fibrinolytic therapy [5] . Given these shortcomings in meeting the goals and accepted standard of care for patients presenting with STEMI, the objective of this review is to outline available reperfusion options (both their safety and efficacy) that can then form the basis for formulating an evidence-based framework and strategy for timely and effective coronary reperfusion.
Reperfusion strategy
As per the ACC/AHA 2007 guidelines, the goal of the medical system is to facilitate rapid recognition and treatment of patients who present acutely with STEMI so that door-to-needle (or the first medical contact-toneedle) time for initiation of fibrinolytic therapy can be achieved within 30 min or door-to-balloon (or the first medical contact-to-balloon) time for primary PCI can be achieved within 90 min [4 ] . It also emphasizes the critical determinant that faster time to reperfusion and that the speed of achieving early reperfusion is more important than the modality of reperfusion in reducing morbidity and mortality in patients with STEMI. As electrocardiogram (EKG) findings are the keys in recognizing STEMI patients and deciding which reperfusion strategy is best, it is logical that emergency medical services (EMS) should be encouraged to use prehospital EKG technology, which can facilitate and enhance the speed and accuracy of diagnosing STEMI in the field prior to initiating patient transport to a hospital and then categorizing patients accordingly for the treatment strategy. Further treatment of these patients in the United States is provided by two types of hospitals -PCI-capable hospitals and PCI-noncapable hospitals. Accordingly, the choice of reperfusion should be based on which reperfusion modality exists at the hospital to which the patient is being transferred (Fig. 1) [4 ] . Whatever reperfusion strategy is adopted, the goal of therapy is to provide prompt reperfusion to the ischemic zone as early as possible. ACC/AHA guidelines encourage that if EMS has the capability and requisite training to administer fibrinolytic therapy in the field and if the patient qualifies for it, then EMS personnel should provide fibrinolytic therapy to the patient, ideally within 30 min of arrival at the scene. The ACC/AHA guidelines 614 Ischemic heart disease Figure 1 Options for transportation of ST-segment elevation myocardial infarction patients and initial reperfusion treatment goals EMS, emergency medical services; PCI, percutaneous coronary intervention. y, medical system goals for EMS transport; Ã, goal for total ischemic time.
Reproduced with permission from [4 ] .
further emphasize that because many hospitals in the United States are not equipped with 24/7 PCI capability, so the ready access to primary PCI should not obscure or deter the important choice of proceeding expediently with fibrinolytic therapy ( 
Primary percutaneous coronary intervention
Multiple randomized controlled trials have demonstrated the superiority of rapid primary PCI over fibrinolysis in STEMI [6] [7] [8] [9] [10] [11] . As noted above, as a large number of US hospitals do not have the capability of meeting the time goal of primary PCI in less than 90 min, fibrinolytic therapy should be considered the preferred approach in reducing morbidity and mortality in acute STEMI. This is also supported by the findings from the Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) and Primary Angioplasty in Patients Transported From General Community Hospitals to Specialized PTCA Units With or Without Emergency Thrombolysis-2 (PRAGUE-2) trials, which suggested that earlier-presenting patients (within 2-3 h) had similar or lower mortality with fibrinolysis as compared with primary PCI [12, 13] .
The early open artery theory suggests that the benefits of reperfusion in patients with STEMI are directly related to the speed and completeness with which patency of the infarct-related coronary artery is reestablished. Mortality has been shown to be lower among patients in whom Thrombolysis in Myocardial Infarction (TIMI) flow grade 2-3 is achieved, compared with TIMI flow grade 0-1, within 90 min after acute MI [14] . However, the recently published Occluded Artery Trial (OAT) showed that PCI provided no delayed benefit over optimal medical therapy alone in stable patients with persistent total occlusion of the infarct-related coronary artery who presented to hospital 3-28 days after acute MI and who met criteria for high risk [15] , indicating that there is no indication to open an occluded vessel outside the therapeutic window in an asymptomatic patient post-STEMI. Even though primary PCI has an established beneficial role in STEMI, there are still many practical limitations that delay achieving the ideal goal time for primary PCI. Door-to-balloon times of less than 90 min are attained in only approximately one-third of patients who do not require transfer [16] and in a much smaller proportion of patients presenting to hospitals without ready access to primary PCI. Real-world data from the National Registry of Myocardial Infarction (NRMI)-3 and NRMI-4 databases (n ¼ 4278) showed that total door-to-balloon times of less than 90 and 120 min were achieved in only 4.2 and 16.2%, respectively, of STEMI patients transferred for PCI (median 180 min) [17] . NRMI-3 and NRMI-4 data suggested hospital presentation during off hours as an important factor associated with delayed treatment [17] . Thus, both circadian and septadian factors (time of day and day of week, respectively), as well as the institutional ability to activate the cardiac catheterization laboratory in an expedient manner, must be considered when a reperfusion strategy is selected. Additionally, institutional volume of primary PCI is another factor that influences the clinical outcomes following PCI, with significantly better outcomes achieved in higher volume centers [18, 19] .
Facilitated PCI is another strategy that refers to planned immediate PCI after administration of an initial pharmacological regimen intended to improve coronary patency before the procedure. These regimens have included high-dose heparin, platelet glycoprotein IIb/IIIa inhibitors, full-dose or reduced-dose fibrinolytic therapy, and the combination of a glycoprotein IIb/IIIa inhibitor with a reduced-dose fibrinolytic agent (e.g., fibrinolytic dose typically reduced 50%). Despite the potential advantages, clinical trials of facilitated PCI have not demonstrated any benefit in reducing infarct size or improving outcomes [20, 21] . In the recently published Facilitate
Acute ST-segment elevation myocardial infarction Boden and Gupta 615 [23] [24] [25] [26] [27] . In the recently presented study at ACC meeting, Trial of Routine ANgioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) [28 ] suggested that a strategy of transferring STEMI patients for PCI within 6 h of receiving thrombolysis at a non-PCI center is superior to the more standard wait-and-see strategy of pharmacologic reperfusion alone.
Overall, PCI has tremendously advanced the care of STEMI patients when used in appropriate clinical, temporal, and logistical settings. However, it is now accepted that when the criteria required for optimal benefit of PCI cannot be met due to logistical and operational limitations, then the early benefit of pharmacological reperfusion should not be withheld from the STEMI patients.
Pharmacological reperfusion
An analysis of 21 randomized clinical trials has shown that as PCI-related time delay increased, absolute mortality reduction at 4-6 weeks favoring primary PCI against fibrinolysis decreased (0.94% decrease per additional 10-min delay; P ¼ 0.006) (Fig. 2) , with apparent equivalence after a PCI-related time delay of 62 min [29] . The ACC/AHA clinical practice guidelines have suggested that fibrinolysis be generally preferred when there is a delay to implementing an invasive strategy such that door-to-balloon time minus door-to-needle time exceeds 1 h. This emphasizes on the potential of prehospital fibrinolysis of the STEMI by the EMS.
Prehospital fibrinolysis
Prehospital fibrinolysis can significantly decrease the time from symptom onset to treatment [30] [31] [32] [33] . Prehospital fibrinolysis results in resolution of ST segment earlier than historical controls indicating a decrease in time to reperfuse [30] and improved outcomes with decrease in mortality (Fig. 3) [31, 33] . In the CAPTIM trial, when prehospital fibrinolysis was compared with transfer to a hospital for immediate PCI, there was no statistically significant between-treatment difference regarding the composite primary end point (death, nonfatal reinfarction, and nonfatal disabling stroke within 30 days) or mortality, suggesting that PCI did not confer an event-free survival advantage [34] . Prehospital fibrinolysis may also decrease time to treatment in other settings, including rural or congested urban areas where transportation times are long, as well as areas in which primary PCI facilities are not immediately available or where time to mobilize the appropriate team may be excessive. Further, the development of bolus and of nonweight-based dosing as alternatives to intravenous (i.v.) infusion regimens with dosing based on body weight has the potential to simplify fibrinolytic administration [33] [34] [35] , which may be important in the prehospital setting especially by the EMS. But due to lack of financial support and fear of legal liabilities for making critical decisions, the use of prehospital fibrinolysis has been underutilized especially in the rural parts of the United States.
Although bleeding is the major risk associated with fibrinolytic therapy with major bleeding seen in about 5-6% of the patients [36, 37] , it may be reduced by using more fibrin-specific agents and by more careful use of dose-adjusted heparin. The ACC/AHA clinical practice guidelines recommend that patients undergoing reperfusion with fibrinolytics should receive anticoagulant therapy for a minimum of 48 h and preferably for the duration of the index hospitalization, up to 8 days [4 ]. The various anticoagulation doses [4 ] recommended are unfractionated heparin (UFH) dose [an initial i.v. bolus 60 U/kg (maximum 4000 U)] followed by an i.v. infusion of 12 U/kg/h (maximum 1000 U/h) initially, adjusted to maintain the activated partial thromboplastin time at 1.5-2.0 times control; or enoxaparin dose: for patients less than 75 years of age, an initial 30 mg i.v. bolus is given, followed 15 min later by subcutaneous injections of 1.0 mg/kg every 12 h; for patients at least 75 years of age, the initial i.v. bolus is eliminated and the subcutaneous dose is reduced to 0.75 mg/kg every 12 h (provided the serum creatinine is less than 2.5 mg/dl in men and 2.0 mg/dl in women); or fondaparinux dose: an initial 2.5 mg administered intravenously, followed subsequently by subcutaneous injections of 2.5 mg once daily (provided serum creatinine is less than 3.0 mg/dl). But due to the risk of catheter thrombosis with the use of fondaparinux alone as seen in Organization for the Assessment of Strategies for Ischemic Syndromes (OASIS-6) trial [38] , the ACC/AHA recommends that fondaparinux should not be used as the sole anticoagulant during PCI but should be coupled with an additional agent that has anti-IIa activity to ameliorate the risk of catheter complications, preferably UFH [4 ] .
Antiplatelet therapy
The Clopidogrel and Metoprolol in Myocardial Infarction Trial/Second Chinese Cardiac Study (COMMIT-CCS2) [39] and Clopidogrel as Adjunctive Reperfusion Therapy -Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI-28) [40] studies have provided evidence for the benefit of adding clopidogrel to aspirin in patients undergoing fibrinolytic therapy. Accordingly, the ACC/AHA clinical practice guidelines have recommended that clopidogrel 75 mg/day orally should be added to aspirin in patients with STEMI, regardless of whether they undergo reperfusion with fibrinolytic therapy or do not receive reperfusion therapy [4 ] . But due to the uncertain safety and efficacy of the loading dose of clopidogrel in elderly patients presenting with STEMI, the ACC/AHA guidelines suggest not to give the loading dose of clopidogrel to patients aged more than 75 years, especially when they are treated with fibrinolytics.
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Conclusion
In conclusion, whatever reperfusion strategy is adopted, the ultimate goal should be to obtain prompt and effective reperfusion of ischemic myocardium as early as possible. If immediately available (or with no more than an anticipated transfer delay of 60 min to a PCIcapable facility), primary angioplasty should be undertaken as the preferred reperfusion choice, given its superior performance in achieving higher levels of TIMI III flow and better clinical outcomes with lower complications rates. There is a critical need to educate patients about the warning signs and symptoms of acute MI and the need to readily access the 911 EMS system. A major challenge is to address better strategies to reduce EMS transfer delays between hospitals in STEMI patients who initially present to non-PCIcapable hospitals, which is probably the largest impediment faced in the United States. Additionally, there is a need to better coordinate early STEMI diagnosis in the field ideally and using transtelephonic monitoring to directly transmit ECG tracings to tertiary sites so that community hospitals, if feasible, can be bypassed and that patients can be more quickly transported to a PCIcapable hospital.
The concept of a 'Hub and Spoke Network model' [41] is a novel approach to more coordinated STEMI management, particularly for community hospitals. If tertiary hospitals with 24/7 primary PCI capability can more effectively partner with community hospitals and develop common protocols and algorithms, what may emerge is better integrated delivery of care for STEMI patients who present to the majority of US hospitals. This model consists of establishing integrated systems of care between participating hospitals without cardiac catheterization capability (so-called 'spoke hospitals') and high-volume tertiary centers ('hub hospitals') wherein the early management of STEMI can be systematically coordinated by emergency medicine and cardiology personnel at all participating hospitals.
The most efficacious and safe strategy for the treatment of STEMI patients involves an integrated approach of highly organized networks of EMS, emergency medicine physicians, and cardiologists to enhance the availability and use of primary PCI and to promote the use of fibrinolytic therapy, especially prehospital fibrinolysis, when primary PCI is not available. A so-called 'drip and ship' strategy may prove to be the most beneficial approach to ensuring that STEMI patients who receive an initial thrombolytic approach can be cared for quickly in a dedicated healthcare environment where PCI can be performed urgently, as needed clinically.
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